product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
CD44 Monoclonal Antibody (156-3C11)
catalog :
MA5-13890
quantity :
500 uL
price :
US 437.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
156-3C11
reactivity :
green monkey, human
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - paraffin section, blocking or activating experiments, western blot knockout validation, immunocytochemistry knockout validation
more info or order :
Invitrogen product webpage
citations: 89
Published Application/Species/Sample/DilutionReference
  • immunocytochemistry knockout validation; human; 2 ug/ml; loading ...; fig 1d
  • western blot knockout validation; human; 1:1000; loading ...; fig 1f, 1s1b, 3e
  • immunohistochemistry - paraffin section; human; loading ...; fig 4s2b
Ramos E, Tsai C, Jia Y, Cao Y, Manu M, Taftaf R, et al. Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity. elife. 2022;11: pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:250; loading ...; fig 3h
  • western blot; human; 1:250; loading ...; fig 5d
Moreno Rodríguez M, Perez S, Nadeem M, Malek Ahmadi M, Mufson E. Frontal cortex chitinase and pentraxin neuroinflammatory alterations during the progression of Alzheimer's disease. J Neuroinflammation. 2020;17:58 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 8i
Sang Y, Li Y, Zhang Y, Alvarez A, Yu B, Zhang W, et al. CDK5-dependent phosphorylation and nuclear translocation of TRIM59 promotes macroH2A1 ubiquitination and tumorigenicity. Nat Commun. 2019;10:4013 pubmed publisher
  • immunocytochemistry; human; loading ...; fig 2e
Chang Y, Lin T, Campbell M, Pan C, Lee S, Lee H, et al. REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer. Sci Rep. 2017;7:42795 pubmed publisher
  • blocking or activating experiments; human; loading ...; fig 4c
Horvatinovich J, Grogan E, Norris M, Steinkasserer A, Lemos H, Mellor A, et al. Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes. J Immunol. 2017;198:2286-2301 pubmed publisher
  • flow cytometry; human; fig 2b
Yoo S, Leng L, Kim B, Du X, Tilstam P, Kim K, et al. MIF allele-dependent regulation of the MIF coreceptor CD44 and role in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016;113:E7917-E7926 pubmed
  • immunohistochemistry - paraffin section; human; 1:800; loading ...; fig 2b
Zhao H, Tang H, Xiao Q, He M, Zhao L, Fu Y, et al. The Hedgehog signaling pathway is associated with poor prognosis in breast cancer patients with the CD44+/CD24? phenotype. Mol Med Rep. 2016;14:5261-5270 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 3a
Horimoto Y, Arakawa A, Sasahara N, Tanabe M, Sai S, Himuro T, et al. Combination of Cancer Stem Cell Markers CD44 and CD24 Is Superior to ALDH1 as a Prognostic Indicator in Breast Cancer Patients with Distant Metastases. PLoS ONE. 2016;11:e0165253 pubmed publisher
  • immunocytochemistry; human; loading ...; fig 1d
  • western blot; human; loading ...; fig 2b
Bellerby R, Smith C, Kyme S, Gee J, Gunthert U, Green A, et al. Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. Front Oncol. 2016;6:145 pubmed publisher
  • immunohistochemistry; human; fig 1
Seo A, Lee H, Kim E, Jang M, Kim Y, Kim J, et al. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. Br J Cancer. 2016;114:1109-16 pubmed publisher
  • flow cytometry; human; 1:200; fig 3
Lee T, Liu C, Chang Y, Nieh S, Lin Y, Jao S, et al. Increased chemoresistance via Snail-Raf kinase inhibitor protein signaling in colorectal cancer in response to a nicotine derivative. Oncotarget. 2016;7:23512-20 pubmed publisher
  • immunohistochemistry; human; fig 1
Binmadi N, Elsissi A, Elsissi N. Expression of cell adhesion molecule CD44 in mucoepidermoid carcinoma and its association with the tumor behavior. Head Face Med. 2016;12:8 pubmed publisher
  • immunohistochemistry; human; 1:100; fig e5
Shu S, Lin C, He H, Witwicki R, Tabassum D, Roberts J, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413-417 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
AbdElazeem M, El Sayed M. The pattern of CD44 and matrix metalloproteinase 9 expression is a useful predictor of ulcerative colitis-associated dysplasia and neoplasia. Ann Diagn Pathol. 2015;19:369-74 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100-1:200; fig 2
Ceyran A, Şenol S, Güzelmeriç F, Tunçer E, Tongut A, Özbek B, et al. Effects of hypoxia and its relationship with apoptosis, stem cells, and angiogenesis on the thymus of children with congenital heart defects: a morphological and immunohistochemical study. Int J Clin Exp Pathol. 2015;8:8038-47 pubmed
  • immunohistochemistry; human; 1:25
KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed publisher
  • immunohistochemistry - paraffin section; human
Sanguinetti A, Santini D, Bonafè M, Taffurelli M, Avenia N. Interleukin-6 and pro inflammatory status in the breast tumor microenvironment. World J Surg Oncol. 2015;13:129 pubmed publisher
  • immunohistochemistry; human; fig 9
Westcott J, Prechtl A, Maine E, Dang T, Esparza M, Sun H, et al. An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. J Clin Invest. 2015;125:1927-43 pubmed publisher
  • immunocytochemistry; human; 4 ug/ml
Rappa G, Green T, Karbanová J, Corbeil D, Lorico A. Tetraspanin CD9 determines invasiveness and tumorigenicity of human breast cancer cells. Oncotarget. 2015;6:7970-91 pubmed
  • immunohistochemistry - paraffin section; human; 1:2000; tbl 2
Koo D, Lee H, Ahn J, Yoon D, Kim S, Gong G, et al. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol. 2015;36:5865-71 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:200; fig 1
Kaygusuz E. Immunohistochemical expression of CD44 standard and E-cadherin in atypical leiomyoma and leiomyosarcoma of the uterus. J Obstet Gynaecol. 2015;35:279-82 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; tbl 3
Gwak J, Kim H, Kim E, Chung Y, Yun S, Seo A, et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat. 2014;147:39-49 pubmed publisher
  • flow cytometry; human; 1:200
He Q, Luo X, Wang K, Zhou Q, Ao H, Yang Y, et al. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem. 2014;33:173-84 pubmed publisher
  • immunohistochemistry; human
Almendro V, Kim H, Cheng Y, Gonen M, Itzkovitz S, Argani P, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014;74:1338-48 pubmed publisher
  • immunohistochemistry; human
Wu Y, Sarkissyan M, Elshimali Y, Vadgama J. Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN. PLoS ONE. 2013;8:e78259 pubmed publisher
  • immunohistochemistry; human; 1:200
Mylona E, Melissaris S, Giannopoulou I, Theohari I, Papadimitriou C, Keramopoulos A, et al. Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive tumor phenotype and identification of patients at high risk for relapse. Eur J Surg Oncol. 2014;40:289-96 pubmed publisher
  • immunohistochemistry; human; 1:2000
Adamczyk A, Niemiec J, Ambicka A, Mucha Małecka A, Mituś J, Rys J. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy. J Mol Histol. 2014;45:35-45 pubmed publisher
  • immunohistochemistry; human; 1:100
Ohara Y, Oda T, Sugano M, Hashimoto S, Enomoto T, Yamada K, et al. Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer. Cancer Sci. 2013;104:1127-34 pubmed publisher
  • immunocytochemistry; human; 1:200
  • immunohistochemistry; human
Jambal P, Badtke M, Harrell J, Borges V, Post M, Sollender G, et al. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013;137:431-48 pubmed publisher
  • immunoprecipitation; human
  • immunocytochemistry; human
  • western blot; human
Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer. 2012;12:458 pubmed publisher
  • immunohistochemistry; human; 1:200
Currie M, Beardsley B, Harris G, Gunningham S, Dachs G, Dijkstra B, et al. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum Pathol. 2013;44:402-11 pubmed publisher
  • immunohistochemistry; human; 1:800
Jeong B, Liang Z, Huang S, Lim J, Kim J, Lee H. CD44 is associated with tumor recurrence and is an independent poor prognostic factor for patients with localized clear cell renal cell carcinoma after nephrectomy. Exp Ther Med. 2012;3:811-817 pubmed
  • immunohistochemistry; human
Tajima H, Ohta T, Kitagawa H, Okamoto K, Sakai S, Kinoshita J, et al. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Oncol Lett. 2012;3:1186-1190 pubmed
  • immunohistochemistry; human; 1:100
Kagara N, Huynh K, Kuo C, Okano H, Sim M, Elashoff D, et al. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer. Am J Pathol. 2012;181:257-67 pubmed publisher
  • immunohistochemistry; human; 1:800
Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, et al. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome. Oncology. 2012;82:168-74 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100
Jung Y, Joo K, Seong D, Choi Y, Kong D, Kim Y, et al. Identification of prognostic biomarkers for glioblastomas using protein expression profiling. Int J Oncol. 2012;40:1122-32 pubmed publisher
  • immunohistochemistry; human
  • western blot; human
Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res. 2012;22:259-72 pubmed publisher
  • immunocytochemistry; human
Marotta L, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker S, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44?CD24? stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121:2723-35 pubmed publisher
  • immunohistochemistry; human
Demirag F, Cakir E, Alpar S, Tastepe I, Kaya S. Expression of CD44 and MMP-2: possible association with histopathological features of pleuro-pulmonary solitary fibrous tumors. Turk Patoloji Derg. 2011;27:127-33 pubmed publisher
  • immunohistochemistry; human; 1:200
Lee H, Kim J, Kim Y, Choi S, Kim S, Kang E, et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer. 2011;104:1730-8 pubmed publisher
  • immunohistochemistry; human; 1:800
Ween M, Oehler M, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci. 2011;12:1009-29 pubmed publisher
  • flow cytometry; human
  • immunocytochemistry; human
  • immunohistochemistry; human
Anido J, Sáez Borderías A, Gonzàlez Juncà A, Rodón L, Folch G, Carmona M, et al. TGF-? Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell. 2010;18:655-68 pubmed publisher
  • immunocytochemistry; human; 1:150
Karaoz E, Okçu A, Gacar G, Sağlam O, Yuruker S, Kenar H. A comprehensive characterization study of human bone marrow mscs with an emphasis on molecular and ultrastructural properties. J Cell Physiol. 2011;226:1367-82 pubmed publisher
  • immunohistochemistry; human
Balic M, Rapp N, Stanzer S, Lin H, Strutz J, Szkandera J, et al. Novel immunofluorescence protocol for multimarker assessment of putative disseminating breast cancer stem cells. Appl Immunohistochem Mol Morphol. 2011;19:33-40 pubmed publisher
  • immunohistochemistry; human; 1:100
Kawasaki H, Ogura H, Arai Y, Baba S, Kosugi I, Tsutsui Y, et al. Aggressive progression of breast cancer with microscopic pulmonary emboli possessing a stem cell-like phenotype independent of its origin. Pathol Int. 2010;60:228-34 pubmed publisher
  • immunohistochemistry; human
Seegmiller A, Garcia R, Huang R, Maleki A, Karandikar N, Chen W. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol. 2010;23:909-20 pubmed publisher
  • immunohistochemistry; human; 1:200
Park S, Gonen M, Kim H, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest. 2010;120:636-44 pubmed publisher
  • immunohistochemistry; human; 1:100
Gunia S, May M, Koch S, Dietel M, Erbersdobler A. Expression of CD44s in incidental prostate cancer is more strongly associated with Gleason scores on subsequent radical prostatectomies than conventional prognostic parameters. Pathobiology. 2009;76:286-92 pubmed publisher
  • immunohistochemistry; human
Bogusz A, Seegmiller A, Garcia R, Shang P, Ashfaq R, Chen W. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol. 2009;132:597-605 pubmed publisher
  • immunocytochemistry; human; 1:1000
  • western blot; human; 1:2000
Dittmer A, Hohlfeld K, Lützkendorf J, Müller L, Dittmer J. Human mesenchymal stem cells induce E-cadherin degradation in breast carcinoma spheroids by activating ADAM10. Cell Mol Life Sci. 2009;66:3053-65 pubmed publisher
  • immunohistochemistry; human
Hong S, Wen J, Bang S, Park S, Song S. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int J Cancer. 2009;125:2323-31 pubmed publisher
  • immunohistochemistry; human; 1:100
Tanei T, Morimoto K, Shimazu K, Kim S, Tanji Y, Taguchi T, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234-41 pubmed publisher
  • immunohistochemistry; human; 1:100
Snyder E, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Lab Invest. 2009;89:857-66 pubmed publisher
  • immunohistochemistry; human
Nakajima K, Abe T, Tanaka M, Hara Y. Periodontal tissue engineering by transplantation of multilayered sheets of phenotypically modified gingival fibroblasts. J Periodontal Res. 2008;43:681-8 pubmed publisher
  • immunohistochemistry; human; 1:800
Honeth G, Bendahl P, Ringner M, Saal L, Gruvberger Saal S, Lövgren K, et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 2008;10:R53 pubmed publisher
  • immunohistochemistry; human; 1:200
Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, et al. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol. 2008;39:1096-102 pubmed publisher
  • flow cytometry; human
Paupert J, Mansat De Mas V, Demur C, Salles B, Muller C. Cell-surface MMP-9 regulates the invasive capacity of leukemia blast cells with monocytic features. Cell Cycle. 2008;7:1047-53 pubmed
  • immunohistochemistry; human
Horwitz K, Dye W, Harrell J, Kabos P, Sartorius C. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A. 2008;105:5774-9 pubmed publisher
  • immunohistochemistry; human
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117:3988-4002 pubmed
  • immunohistochemistry; human; 1:200
Harrell J, Dye W, Harvell D, Pinto M, Jedlicka P, Sartorius C, et al. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007;67:10582-91 pubmed
  • immunohistochemistry; human; 1:2000
Charafe Jauffret E, Monville F, Bertucci F, Esterni B, Ginestier C, Finetti P, et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer. 2007;121:1779-85 pubmed
  • immunocytochemistry; human
Ricciardelli C, Russell D, Ween M, Mayne K, Suwiwat S, Byers S, et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem. 2007;282:10814-25 pubmed
  • immunohistochemistry; human
Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006;12:5615-21 pubmed
  • immunohistochemistry; human
Kuo K, Liang C, Hsiao C, Lin C, Chen C, Sheu B, et al. Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol. 2006;19:1570-7 pubmed
  • immunohistochemistry; human
Harrell J, Dye W, Allred D, Jedlicka P, Spoelstra N, Sartorius C, et al. Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res. 2006;66:9308-15 pubmed
  • immunocytochemistry; human; 1 ug/ml
  • immunohistochemistry; human
Zhuo L, Kanamori A, Kannagi R, Itano N, Wu J, Hamaguchi M, et al. SHAP potentiates the CD44-mediated leukocyte adhesion to the hyaluronan substratum. J Biol Chem. 2006;281:20303-14 pubmed
  • immunohistochemistry; human; 1:100
Lo H, Xia W, Wei Y, Ali Seyed M, Huang S, Hung M. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005;65:338-48 pubmed
Haffner M, Saiz A, Darrow M, Judge S, Laun T, Arora A, et al. Effect of ALDH1A1 and CD44 on Survival and Disease Recurrence in Patients With Osteosarcoma. Cureus. 2024;16:e52404 pubmed publisher
Lin C, Lin L, Chen T, Ye Y, Chiang B. The expression of nicotinic acetylcholine receptor subunits and their associations with local immune cells and prognosis in oral squamous cell carcinoma. Cancer Med. 2023;12:18918-18930 pubmed publisher
Balduit A, Vidergar R, Zacchi P, Mangogna A, Agostinis C, Grandolfo M, et al. Complement protein C1q stimulates hyaluronic acid degradation via gC1qR/HABP1/p32 in malignant pleural mesothelioma. Front Immunol. 2023;14:1151194 pubmed publisher
Lu G, Xu Y, Liu Q, Chen M, Sun H, Wang P, et al. An instantly fixable and self-adaptive scaffold for skull regeneration by autologous stem cell recruitment and angiogenesis. Nat Commun. 2022;13:2499 pubmed publisher
Voeltzel T, Fossard G, Degaud M, Geistlich K, Gadot N, Jeanpierre S, et al. A minimal standardized human bone marrow microphysiological system to assess resident cell behavior during normal and pathological processes. Biomater Sci. 2022;10:485-498 pubmed publisher
Jun S, Yoon H, Yoon J, Jeon S, Lee J, Halder D, et al. The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients' Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers. Cancers (Basel). 2021;13: pubmed publisher
Dempsey M, Woodford Berry O, Darling E. Quantification of Antibody Persistence for Cell Surface Protein Labeling. Cell Mol Bioeng. 2021;14:267-277 pubmed publisher
Biesaga B, Ko x142 odziej Rzepa M, Janecka Wid x142 a A, S x142 onina D, Halaszka K, Przewo x17a nik M, et al. Lack of CD44 overexpression and application of concurrent chemoradiotherapy with cisplatin independently indicate excellent prognosis in patients with HPV-positive oropharyngeal cancer. Tumour Biol. 2021;43:99-113 pubmed publisher
Lee E, Lokman N, Oehler M, Ricciardelli C, Grützner F. A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer. Cancers (Basel). 2020;13: pubmed publisher
Cooper T, Logue J, Liu D, Perry D, Hart R, Hischak A, et al. Filoviruses Infect Rhesus Macaque Synoviocytes in Vivo and Primary Human Synoviocytes in Vitro. Am J Pathol. 2020;190:1867-1880 pubmed publisher
Kawaguchi M, Dashzeveg N, Cao Y, Jia Y, Liu X, Shen Y, et al. Extracellular Domains I and II of cell-surface glycoprotein CD44 mediate its trans-homophilic dimerization and tumor cluster aggregation. J Biol Chem. 2020;295:2640-2649 pubmed publisher
Chang C, Seibel A, Avendano A, Cortes Medina M, Song J. Distinguishing Specific CXCL12 Isoforms on Their Angiogenesis and Vascular Permeability Promoting Properties. Adv Healthc Mater. 2020;9:e1901399 pubmed publisher
Romswinkel A, Infanger M, Dietz C, Strube F, Kraus A. The Role of C-X-C Chemokine Receptor Type 4 (CXCR4) in Cell Adherence and Spheroid Formation of Human Ewing's Sarcoma Cells under Simulated Microgravity. Int J Mol Sci. 2019;20: pubmed publisher
Verigos J, Karakaidos P, Kordias D, Papoudou Bai A, Evangelou Z, Harissis H, et al. The Histone Demethylase LSD1/ΚDM1A Mediates Chemoresistance in Breast Cancer via Regulation of a Stem Cell Program. Cancers (Basel). 2019;11: pubmed publisher
Yuk H, Jeong C, Kwak C, Kim H, Moon K, Ku J. Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification. BMC Cancer. 2019;19:897 pubmed publisher
Wang M, Nagle R, Knudsen B, Cress A, Rogers G. Centrosome loss results in an unstable genome and malignant prostate tumors. Oncogene. 2019;: pubmed publisher
Hellman U, Engström Laurent A, Larsson A, Lindqvist U. Hyaluronan concentration and molecular mass in psoriatic arthritis: biomarkers of disease severity, resistance to treatment, and outcome. Scand J Rheumatol. 2019;48:284-293 pubmed publisher
Holm A, Hellman U, Laurent C, Laurell G, Nylander K, Olofsson K. Hyaluronan in vocal folds and false vocal folds in patients with recurrent respiratory papillomatosis. Acta Otolaryngol. 2018;138:1020-1027 pubmed publisher
Andrews A, Warner K, Rodriguez Ramirez C, Pearson A, Nör F, Zhang Z, et al. Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2-p53 Interaction in Mucoepidermoid Carcinoma. Clin Cancer Res. 2019;25:1588-1600 pubmed publisher
Liao S, Gan L, Qin W, Liu C, Mei Z. Inhibition of GSK3 and MEK induced cancer stem cell generation via the Wnt and MEK signaling pathways. Oncol Rep. 2018;40:2005-2013 pubmed publisher
Kowtharapu B, Murin R, Jünemann A, Stachs O. Role of Corneal Stromal Cells on Epithelial Cell Function during Wound Healing. Int J Mol Sci. 2018;19: pubmed publisher
Freedland S, Seligson D, Liu A, Pantuck A, Paik S, Horvath S, et al. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate. 2003;55:71-80 pubmed
product information
Product Type :
Antibody
Product Name :
CD44 Monoclonal Antibody (156-3C11)
Catalog # :
MA5-13890
Quantity :
500 uL
Price :
US 437.00
Clonality :
Monoclonal
Purity :
Protein A/G
Host :
Mouse
Reactivity :
Baboon, Human, Non-human primate
Applications :
Flow Cytometry: 2 ug/test, Immunocytochemistry: 1:200, Immunohistochemistry (Paraffin): 1-2 ug/mL, Immunoprecipitation: 2 ug/mL, Western Blot: 1-2 ug/mL
Species :
Baboon, Human, Non-human primate
Clone :
156-3C11
Isotype :
IgG2a, kappa
Storage :
4 C
Description :
CD44 cell surface antigen is a 100 kDa type 1 transmembrane glycoprotein widely expressed on human leucocytes, white matter of the brain and by some epithelial cells of the intestine and breast. Several isoforms of CD44 exist, including the predominant CD44H isoform detected in many normal tissues. CD44 is a receptor for hyaluronic acid (HA) and is involved in cell-cell interactions, cell adhesion and migration. CD44 also participates in a wide variety of cellular functions including lymphocyte activation, recirculation and homing. CD44 expression may be up-regulated upon some carcinomas, and it has been speculated that this may be related to metastatic potential. CD44 is expressed by hematopoietic, non-hematopoietic cells, epithelial tissues, and to filopodia in cultured keratinocytes. Further, bone marrow myeloid cells and memory T cells express CD44 at high levels, and peripheral B and T cells can upregulate the expression of CD44 in response to certain stimulatory events. Transcripts for the CD44 gene undergo complex alternative splicing that results in many functionally distinct isoforms, however, the full-length nature of some of these variants have not been determined. Alternative splicing is the basis for the structural and functional diversity of the CD44 protein. Diseases associated with CD44 dysfunction include superficial keratitis and lichen sclerosus. CD44 also may be related to tumor metastasis formation.
Immunogen :
Stimulated human leukocytes
Format :
Liquid
Applications w/Dilutions :
Flow Cytometry: 2 ug/test, Immunocytochemistry: 1:200, Immunohistochemistry (Paraffin): 1-2 ug/mL, Immunoprecipitation: 2 ug/mL, Western Blot: 1-2 ug/mL
Aliases :
AU023126; AW121933; AW146109; Bovine CD44; CD44; CD44 antigen; CD44 antigen-like protein; CD44 molecule; CD44 molecule (Indian blood group); CD44 protein; CD44 variant; CD44A; CD44-like protein; CDW44; cell surface glycoprotein CD44; Cell surface glycoprotein CD44 (hyaluronate binding protein); cell-surface glycoprotein; chondroitin sulfate proteoglycan 8; CSPG8; ECMRIII; ECMR-III; Epican; extracellular matrix receptor III; extracellular matrix receptor-III; GP90 lymphocyte homing/adhesion receptor; HCELL; hematopoietic cell E- and L-selectin ligand; heparan sulfate proteoglycan; HERMES; Hermes antigen; homing function and Indian blood group system; HUTCH-I; hyaluronan receptor; Hyaluronate receptor; IN; LHR; Ly-24; lymphocyte antigen 24; lymphocyte surface antigen precursor CD44; MC56; MDU2; MDU3; METAA; MIC4; PGP I; Pgp1; PGP-1; PGPI; PGP-I; Phagocytic glycoprotein 1; phagocytic glycoprotein I; putative Bos taurus CD44; RHAMM; sCD 44; sCD44; soluble CD 44; soluble CD44
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA